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The efficacy of a novel synthetic antimicrobial peptide (WLBU2) was evaluated against three oral microor-
ganisms (grown planktonically): Streptococcus gordonii, Fusobacterium nucleatum, and Porphyromonas gingivalis.
WLBU2 killed all three species, with F. nucleatum being the most susceptible. WLBU2 also reduced the
bacterial burden of S. gordonii and F. nucleatum biofilms.
With increasing evidence for links between infectious bur-
den and systemic diseases such as coronary artery disease (6,
15, 18), the oral cavity has been shown to be an important
contributor to this systemic microbial bioburden (4, 5, 7, 8, 12).
The microcosm found in the oral cavity comprises more than
700 species of microorganisms (1) arranged as both single-
species and multispecies biofilms. The tooth-associated biofilm
(dental plaque) is the primary etiologic factor associated with
dental caries and periodontal disease. Dental plaque biofilm
formation is a sequential process initiated by adherence of
gram-positive early colonizers to the tooth surface, followed by
a shift to a predominance of more pathogenic gram-negative
anaerobic species (late colonizers) as the biofilm matures. Im-
portantly, Fusobacterium nucleatum serves as an important co-
aggregation bridge between early and late colonizers (9).
The use of topical chemotherapeutic agents that inhibit
plaque formation is an important adjunct in the prevention of
oral diseases such as dental caries and periodontal disease.
Therefore, the development of novel antimicrobial compounds
that are effective against oral microorganisms is an important
aspect of both basic science and commercial oral health re-
search. The lentivirus lytic peptides are one example of this
class of novel compounds (11, 13, 17). A de novo-engineered
derivative of lentivirus lytic peptide, WLBU2, is a 24-amino-
acid peptide that is effective against a broad spectrum of gram-
positive and gram-negative isolates (2). WLBU2 eliminates
Pseudomonas aeruginosa in coculture with human skin fibro-
blasts without detectable adverse effects to the host cells, is
active against Staphylococcus aureus and P. aeruginosa at phys-
iologic NaCl concentrations, and kills P. aeruginosa in human
serum. WLBU2 also eradicates bacteria from ex vivo samples
of whole blood, suggesting it may be suitable for use as a
topical or systemic chemotherapeutic agent in the prevention
and treatment of medically important infections (3). Based on
the need for the development of chemotherapeutics against
oral pathogens and the demonstrated antimicrobial activity of
WLBU2, we hypothesized that oral bacteria would be sensitive
to this peptide.
Using a standard broth dilution assay (17), the potency of
WLBU2 was evaluated against planktonic cultures of Strepto-
coccus gordonii, an early colonizer of dental plaque; F. nuclea-
tum, the important coaggregation “bridging” colonizer; and
Porphyromonas gingivalis, a late colonizer associated with mul-
tiple forms of periodontal disease (9, 14). P. aeruginosa was
used as a positive bacterial control. Bacterial cultures were
propagated in liquid media under appropriate growth condi-
tions (Table 1) to mid-log phase, washed with phosphate buffer
(PB), and suspended in PB such that upon dilution, 105 to 106
CFU/ml was tested in the bacterial killing assay. The bacteria
were incubated with twofold dilutions of the peptide (100 M
to 0.39 M) in 96-well plates in PB at 37°C under appropriate
growth conditions (Table 1). Although WLBU2 reduces viable
counts of P. aeruginosa in seconds in PB (17), a minimum of 20
min is required for killing in serum (3). Since the subgingival
environment contains a serum transudate, a standard 30-min
peptide exposure was selected for this pilot project. Quantifi-
cation of bacterial survival post-peptide exposure was evalu-
ated using serial 10-fold dilutions of control and test wells.
Bacterial colonies were counted at 24 h for S. gordonii and P.
aeruginosa and at 48 h for F. nucleatum and P. gingivalis and
were compared to counts of non-peptide-treated controls to
determine the amount of WLBU2 that reduced the bacterial
counts by 3 orders of magnitude. This level of killing defined
the minimum bactericidal concentration (MBC), assessed in
micromolar concentrations of peptide. The results were ex-
pressed as averages of MBCs obtained from three independent
experiments.
All three species of planktonic oral bacteria were killed by
WLBU2 (Fig. 1). The MBC was between 1 and 2 M for P.
aeruginosa and F. nucleatum, between 12.5 and 25 M for S.
gordonii, and between 50 and 100 M for P. gingivalis. Viable
counts also were assessed for S. gordonii and F. nucleatum
following exposure to comparable micromolar concentrations
of amoxicillin or metronidazole, antibiotics frequently used in
treating periodontal disease (16). There were no significant
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decreases in the viable cell counts of either bacterium follow-
ing these treatments (Tables 2 and 3).
The high concentration required for killing P. gingivalis
strain W83 may be due to the encapsulated nature of this strain
or the presence of the numerous proteolytic enzymes released
by this bacterium. This will be assessed in future studies. How-
ever, the MBCs for two different strains of F. nucleatum were
between 1 and 2 M, consistent with results evaluating the
specificity of WLBU2 against numerous P. aeruginosa strains
(2). Interestingly, both strains of F. nucleatum were far more
susceptible to killing by this novel peptide than either S. gor-
donii or P. gingivalis when grown as planktonic cells. Because F.
nucleatum is recognized as an important “bridging” bacterium
between the less pathogenic early colonizers and the more
pathogenic late colonizers of the plaque biofilm, antimicrobial
agents disrupting this bridge before the development of a ma-
ture biofilm could interfere with plaque maturation.
The effectiveness of WLBU2 was assessed against single-spe-
cies oral biofilms developed on individual rigid gas-permeable
lens (RGPL) material (unpublished data). Replicate RGPLs
were coated with fetal bovine serum, washed with sterile phos-
phate-buffered saline (PBS), and incubated with overnight cul-
tures of S. gordonii or F. nucleatum for 24 h under appropriate
conditions (Table 1). After 24 h, the culture medium was carefully
removed without displacing the developing biofilm and was re-
placed with an equal volume of fresh medium daily for 3 days (S.
gordonii) or 4 days (F. nucleatum). The RGPL material was then
washed with sterile PBS to remove nonadherent cells and treated
with either WLBU2, amoxicillin, or metronidazole (25 M for S.
gordonii; 2 M for F. nucleatum) for 30 min under appropriate
conditions (Table 1). Additional replicates treated with PBS
served as controls. Treated and control biofilms were released
from the RGPL into PBS with a sterile cell scraper and disrupted
by vortexing. Serial dilutions were spread onto blood agar plates
in triplicate for determination of CFU.
The results of three replicate experiments demonstrated that
treatment of S. gordonii biofilms with WLBU2 resulted in a
statistically significant decrease in mean cell counts compared
to those for PBS-treated controls. Mean cell counts did not
decrease significantly following treatment with either amoxi-
cillin or metronidazole (Table 2). Similarly, treatment of F.
nucleatum biofilms with these antibiotics did not decrease vi-
able cell counts, while treatment with WLBU2 did lead to
decreased counts. However, the results with WLBU2 were not
statistically significant (Table 3). Taken together, these results
indicate a trend toward the ability of WLBU2 to impact viable
counts of both S. gordonii and F. nucleatum cells grown as
biofilms.
These studies demonstrate activity of WLBU2 against early
and bridging bacteria grown as planktonic cells and known to
be part of oral biofilms. Our results also demonstrate that
WLBU2 can potentially contribute to a lessening of the biobur-
den of a mature single-species biofilm. We hypothesize that the
somewhat limited effect of the peptide on biofilm cells was due
to inefficient penetration beyond the surface layer of bacteria
in the mature biofilm. Consistent with our findings and this
hypothesis, it has been demonstrated previously that mechan-
ical disruption or adjunctive exposure to a surface-active agent
FIG. 1. Dose-dependent killing of oral bacteria and P. aeruginosa
(positive control) by WLBU2. Bacterial cultures (0.5  106 to 1  106
CFU/ml) were treated with twofold dilutions of the peptide in phos-
phate buffer; the log of the number of CFU/ml remaining upon treat-
ment is plotted as a function of peptide concentration.
TABLE 1. Bacterial strains and growth conditions
Bacterial strain Medium Growth conditions
Pseudomonas aeruginosa
ATCC 47085
Todd-Hewitt broth Aerobic
Streptococcus gordonii
ATCC 49818/DL1
Todd-Hewitt broth Aerobic
Fusobacterium nucleatum
ATCC 49256, ATCC
25586
Tryptic soy broth  0.6%
yeast extract
Anaerobic (5% CO2,
10% H2, 85% N2)
Porphyromonas gingivalis
ATCC BAA0308/W83
Mycoplasma broth 
hemin (5 g/ml) 
menadione (1 g/ml)
Anaerobic (5% CO2,
10% H2, 85% N2)
TABLE 2. Viable counts of untreated (PBS) versus treated
S. gordonii cells
Method of cell
growth Treatment
a Total viable count Pb
Planktonic PBS (1.29  0.25)  104
WLBU2 (0.00  0.00)  104 0.001
Amoxicillin (1.35  0.41)  104 NS
Metronidazole (1.22  0.11)  104 NS
Biofilm PBS (2.01  0.08)  107
WLBU2 (0.21  0.02)  107 0.0001
Amoxicillin (1.63  0.11)  107 NS
Metronidazole (1.8  0.14)  107 NS
a All antimicrobials were used at a concentration of 25 M.
b NS, not significant; P  0.05 by a t test that was adjusted when necessary for
unequal variance.
TABLE 3. Viable counts of untreated (PBS) versus treated
F. nucleatum cells
Method of cell
growth Treatment
a Total viable count Pb
Planktonic PBS (1.04  0.08)  107
WLBU2 (0.00  0.00)  107 0.0001
Amoxicillin (1.00  0.15)  107 NS
Metronidazole (1.02  0.07)  107 NS
Biofilm PBS (1.75  0.13)  104
WLBU2 (0.20  0.27)  104 NS
Amoxicillin (2.75  0.07)  104 NS
Metronidazole (2.86  0.57)  104 NS
a All antimicrobials were used at a concentration of 2 M.
b NS, not significant; P  0.05 by a t test that was adjusted when necessary for
unequal variance.
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can enhance peptide killing of biofilm cells (10). Therefore,
future studies will evaluate the efficacy of WLBU2 in combined
therapeutic strategies with a focus on the peptide’s impact on
F. nucleatum as a coaggregating bridge microorganism in mul-
tispecies biofilms.
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